DoW Vision, Investigator-Initiated Research Award | HT942526VRPIIRA

FAQs: FY26 Vision Research Program (VRP) Investigator-Initiated Research Award (IIRA)

What is the FY26 VRP Investigator-Initiated Research Award (IIRA)?

The FY26 Vision Research Program (VRP) Investigator-Initiated Research Award (IIRA) is a grant opportunity run by the U.S. Army Medical Research Acquisition Activity (USAMRAA). It is designed to support investigator-driven projects that can lead to high-impact discoveries or meaningful advances in research and/or clinical care for eye injury and visual dysfunction tied to military exposure.

Who sponsors this funding opportunity?

The sponsoring agency is the Department of the Army, administered through USAMRAA (U.S. Army Medical Research Acquisition Activity).

What is the funding opportunity title and number?

The funding opportunity title is "DoW Vision, Investigator-Initiated Research Award" and the opportunity number is HT942526VRPIIRA.

What research topics does the IIRA aim to support?

The IIRA supports research focused on eye injury and visual dysfunction associated with military exposure, including conditions encountered in military settings. The intent is to fund work that directly supports the VRP mission and targets military-relevant vision problems.

Does the proposed research have to align with specific program priorities?

Yes. A central requirement is that the proposed research must align with at least one of the FY26 VRP Focus Areas, as defined by the program for that fiscal year.

What stage of research is appropriate for this award?

The program is intended to span basic research through early translational efforts. This includes foundational mechanistic studies as well as research designed to move promising concepts closer to practical clinical use.

Are preclinical studies allowed?

Yes. Projects may include preclinical studies.

Is clinical research allowed under this award?

Yes, certain types of clinical research and human-subjects research may be included, as long as the proposed work does not meet the definition of a clinical trial.

Are clinical trials allowed?

No. The award specifically does not allow funding for clinical trials. Proposals should avoid clinical trial designs and instead focus on earlier-stage clinical investigations or other human-subjects research that is not considered a clinical trial.

What is the CFDA number and category for this opportunity?

The listing identifies the opportunity in the science and technology / research and development category with CFDA 12.420.

What does "eligibility described as unrestricted" mean for applicants?

The opportunity describes eligibility as unrestricted, which generally indicates a wide range of applicant organizations may apply, as long as they meet standard federal grant requirements.

How is the award structured in terms of funding levels?

The IIRA is structured with two funding levels. This tiered structure is meant to accommodate projects at different stages of development and with different levels of preliminary evidence, supporting both exploratory concepts and more mature research directions.

What is the Partnering Principal Investigator Option (PPIO)?

Under Funding Level 2, the program offers a Partnering Principal Investigator Option (PPIO). This allows two principal investigators to formally lead the project together as an Initiating PI and a Partnering PI.

When should applicants consider using the PPIO option?

The PPIO is intended for projects that benefit from collaborative, complementary leadership, such as when distinct expertise, resources, or environments across labs or institutions strengthen the project.

How will applications be evaluated?

Applications will be evaluated through a scored peer review process. Review criteria emphasize the strength and logic of the research idea and rationale, the quality of the research strategy and feasibility plan, the potential impact of the work, and the qualifications and suitability of the research personnel.

Is there an additional review after peer review?

Yes. After peer review, a programmatic review considers additional factors, including whether the application matches the intent of the IIRA mechanism, how it contributes to the balance and needs of the overall VRP portfolio, the relative impact compared to other submissions, and how clearly it addresses military health relevance.

How many awards does the program expect to make?

The program anticipates making about five awards.

What is the application deadline?

The original closing date listed for this opportunity is November 12, 2026.

When was this opportunity posted?

The opportunity was created/posted on May 5, 2026.

Is there an award ceiling or maximum budget listed?

No. The award ceiling is not specified in the provided listing. Applicants would need to consult the full funding announcement or program guidelines for budget limits, definitions of the funding levels, and any cost restrictions.

Can an application be shared with another federal institute for possible funding?

Yes. The VRP may share FY26 IIRA applications and peer reviews with the National Eye Institute (NEI), creating a pathway for an application to be considered for independent funding outside the VRP, depending on NEI priorities and processes.

Does sharing with NEI guarantee funding by NEI?

No. The information provided indicates this creates a pathway for consideration, but any independent funding would depend on NEI priorities and processes.

Where can applicants find additional context about the FY26 VRP IIRA?

Additional context is referenced through the CDMRP VRP pre-announcement webpage mentioned in the source.